A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 149 participants.

Also called NCT02260648

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02260648
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02260648. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2018-10-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
Evacetrapib
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02260648
Content hash
aa1aace1c46d8f54be4f7b3dd165bb29829d90a9c1e981102070916a06585162